Keynotes from Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva will showcase how connected platforms and AI can streamline the development of new medicines<\/p>\n
BARCELONA, Spain \u2014 27 May 2025 \u2014 <\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced the biopharma keynote speakers for ³Ô¹Ï±¬ÁÏ R&D and Quality Summit, Europe<\/a>, June 4-5 in Madrid, Spain. Biopharma professionals will convene to learn how the industry is advancing across clinical, regulatory, safety, and quality. The opening keynote will also highlight ³Ô¹Ï±¬ÁÏ AI<\/a>, a major initiative to add AI to the ³Ô¹Ï±¬ÁÏ Vault Platform and ³Ô¹Ï±¬ÁÏ applications to help automate critical functions and improve productivity.\n<\/p>\n \nAs one of the largest gatherings of life sciences leaders in Europe, ³Ô¹Ï±¬ÁÏ R&D and Quality Summit will bring together over 1,400 industry professionals in more than 100 sessions. Novo Nordisk<\/strong> and Recipharm<\/strong> will join Rik Van Mol, senior vice president of R&D and Quality, and Avril England, general manager of ³Ô¹Ï±¬ÁÏ Vault, for the opening keynote to explore the development and manufacturing of new medicines and therapies.\n<\/p>\n \nThe event\u2019s zone keynotes include:<\/p>\n \n\u201cFresh thinking and a strong community are essential to transforming how we bring medicines to patients,\u201d says Rik Van Mol, senior vice president of R&D and Quality. \u201cAt ³Ô¹Ï±¬ÁÏ R&D and Quality Summit, leaders come together to spark new ideas, share breakthroughs, and shape the future of the industry together.\u201d\n<\/p>\n \n³Ô¹Ï±¬ÁÏ R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com\/eu\/Summit<\/a>.\n<\/p>\n Additional Information<\/strong> About ³Ô¹Ï±¬ÁÏ Systems<\/strong> ³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong> ###<\/center><\/p>\n Contact:<\/strong> <\/p>\n Jeremy Whittaker \n
\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>\n<\/p>\n
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.\n<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.\n<\/p>\n
\n³Ô¹Ï±¬ÁÏ Systems
\n+49-695-095-5486
\njeremy.whittaker@veeva.com<\/a>\n<\/p>\n